Prof. Liling Zhang 张利玲
Chief Physician, Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis and individualized treatment of malignant lymphoma, multiple myeloma, lung cancer, breast cancer, gastrointestinal tumors, and head and neck tumors.
Dr. Zhang is Chief Physician, Professor, and Head of the Lymphoma Department at Union Hospital. Dr. Zhang holds a medical doctorate from the University of Hamburg, Germany, focusing on tumor metastasis and liquid biopsy. Since 1999, Dr. Zhang has worked at Union Hospital. Research includes two National Natural Science Foundation projects. By late 2015, Dr. Zhang published over 10 SCI papers.
Professional roles
- Member, Lymphatic and Hematologic Tumors Subcommittee, Geriatric Oncology Professional Committee, Chinese Medical Association
- Member, Lymphoma Professional Committee, China South Clinical Oncology Research Association
- Member, Hematology Branch, Clinical Oncology Professional Committee, Chinese Women Physicians Association
- Vice Chair, Tumor Molecular Markers and Translational Medicine Professional Committee, Hubei Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Liling). Papers usually list the name as Liling Zhang or Zhang L.
Selected publications
97 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Commun Signal, 2026 (senior author): Glutathione S-transferase inhibitor NBDHEX induces ROS-dependent immunogenic cell death and enhances PD-1 blockade in DLBCL. PubMed 41832520
- Oncol Lett, 2026 (senior author): Retrospective analysis of clinical characteristics, treatment outcomes and prognosis of patients with natural killer/T-cell lymphoma. PubMed 41277910
- Oncol Lett, 2025 (senior author): Composite B‑cell lymphoma and extranodal natural killer/T‑cell lymphoma presenting with distinct clone evolution and tumor microenvironment: A report of two cases. PubMed 40351603
- Gene, 2025 (senior author): Identification of oxidative stress-related hub genes for predicting prognosis in diffuse large B-cell lymphoma. PubMed 39500385
- J Chemother, 2024 (senior author): Bendamustine plus Rituximab versus R-miniCHOP: which is better for unfit patients with diffuse larger B-cell lymphoma?. PubMed 37272120
- Oncologist, 2024 (senior author): Tissue-Matched IgH Gene Rearrangement of Circulating Tumor DNA Shows Significant Value in Predicting the Progression of Diffuse Large B Cell Lymphoma. PubMed 38297976
- Front Immunol, 2024 (senior author): Single-cell transcriptome sequencing provides insight into multiple chemotherapy resistance in a patient with refractory DLBCL: a case report. PubMed 38533514
- Oncol Lett, 2023 (senior author): BR vs. R‑miniCHOP in unfit patients with B‑cell non‑Hodgkin lymphoma: A randomized, two‑center, cohort study. PubMed 37664664
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion